Innovation in Drug Research and Development for Prevalent Chronic Diseases

Investment and innovation in drug research and development (R&D) for highly prevalent chronic diseases has stalled in recent decades, despite half of all Americans living with at least one chronic disease. As a result, prevalent chronic diseases are producing immense health care costs as well as preventable suffering and death. On February 22, March 2, and March 8, 2021, the National Academies of Sciences, Engineering, and Medicine, convened a workshop to discuss barriers to innovation in this space and examine strategies and incentives to support equitable, person-centered drug R&D for prevalent chronic diseases.

Table of Contents

• Front Matter
• 1 Introduction
• 2 Person-Centered Drug Research and Development
• 3 New Technologies to Enable Research in Prevalent Chronic Disease
• 4 Investment and Incentives
• 5 Learning from Success
• 6 Lessons Learned for the Future
• 7 Reflections and Final Thoughts
• Appendix A: Workshop Agenda
• Appendix B: Biographical Sketches of Workshop Speakers
<